Back to search
FDAFDA · Food and drugs·Recall number Z-1058-2022

ProterixBio SARS-CoV-2 (RBD) IgG Antibody Test, and associated ProterixBio Dried Blood Spot Collection Kit, no model number

Published May 18, 2022 · Recall initiated: April 17, 2022

Summary

FDA records medical device Class II recall Z-1058-2022, published May 18, 2022 and initiated April 17, 2022. Recalling firm: PROTERIXBIO; Status: Terminated; Reported quantity: 640 kits; Lot: Lots were not coded. All product will be recalled. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

FDA review concluded that the test is insufficiently supported by clinical performance data, and results reported may not have been accurate (false positives or false negatives).

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
PROTERIXBIO
Distributor
Domestic distribution to CA CO FL IA MA MO NH NY OH OK TX VA
Lot
Lots were not coded. All product will be recalled.
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was ProterixBio SARS-CoV-2 (RBD) IgG Antibody Test, and associated ProterixBio Dried Blood Spot Collection Kit, no model number recalled?

Yes. FDA published recall Z-1058-2022 on May 18, 2022. Reported hazard: FDA review concluded that the test is insufficiently supported by clinical performance data, and results reported may not have been accurate (false positives or false negatives).

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail